Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • IHH Healthcare...

    IHH Healthcare completes Fortis Acquisition, Appoints 4 Directors on Board

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-14T16:01:40+05:30  |  Updated On 14 Nov 2018 4:01 PM IST
    IHH Healthcare completes Fortis Acquisition, Appoints 4 Directors on Board

    The board has also approved the appointment of four IHH-NTK's nominees Tan See Leng, Low Soon Teck, Chan Boon Kheng and Bhagat Chintamani Aniruddha as additional directors of Fortis with immediate effect.


    New Delhi: Fortis Healthcare said on Tuesday it has issued 235.3 million equity shares through preferential allotment to IHH Healthcare Berhad for around Rs 40 billion, a move that helps the Malaysian firm take 31.1 per cent stake in the company.


    The allotment has been done at Rs 170 per share.


    IHH has now become the controlling shareholder in the company, Fortis Healthcare said in a filing to BSE.


    The board of Fortis has also approved the appointment of four IHH nominees on the company's board, it added.


    The Board of Directors of the company Tuesday approved the allotment of 23,52,94,117 equity shares through a preferential issue to Northern TK Venture Pte Ltd (a wholly-owned indirect subsidiary of IHH Healthcare Berhad) (IHH-NTK) at Rs 170 per share of Rs 10 face value, it added.


    "Following this, the mandatory open offer for acquiring up to 26 per cent of the expanded capital from the existing shareholders of Fortis at Rs 170 per share for a consideration of up to Rs 33 billion would be completed in due course," it said.



    READ ALSO: Fortis Q2 net loss widens to Rs 142 Crore; IHH transaction to be completed shortly

    "Depending on the shares tendered by the shareholders of Fortis, IHH-NTK would have between 31.1 per cent to 57.1 per cent stake on the expanded capital," Fortis Healthcare said.


    The board has also approved the appointment of four IHH-NTK's nominees Tan See Leng, Low Soon Teck, Chan Boon Kheng and Bhagat Chintamani Aniruddha as additional directors of Fortis with immediate effect, it added.


    Tan See Leng is the managing director (MD) and chief executive officer (CEO) of IHH Healthcare Berhad.


    "The reconstituted Board to have a total of 7 members with 3 current directors and 4 additional directors nominated by IHH," Fortis Healthcare said.


    Commenting on the development, IHH MD and CEO Tan See Leng said: "The acquisition of a controlling stake in Fortis Healthcare, one of the leading healthcare service providers in India, represents a transformational investment for IHH and demonstrates our commitment to invest considerable resources to expand and consolidate our footprint in India."


    "With a clear and holistic strategy in place, we will work closely with Fortis' Board and management to pave the way for Fortis Healthcare to realise its full potential in the long run," he added.


    "I am pleased to announce the completion of the investment by IHH in Fortis. With this, I welcome the new IHH nominated members on the Board," Fortis Healthcare Board of Directors Chairman Ravi Rajagopal said.


    The reconstituted board will actively provide strategic direction and vision to the company and will ensure that the company's focus on clinical excellence, clinical outcomes, patient care and business results remains paramount, he added.


    "The Board will be working closely with management to further strengthen governance and internal control frameworks on par with other leading organisations," Rajagopal said.


    Shares of Fortis Healthcare Ltd closed at Rs 141.80 on BSE, up 1.95 per cent from the previous close.

    Acquisitionadditional directors of FortisBhagat Chintamani AniruddhaChairman Ravi Rajagopalchief executive officerDirectorFortisfortis directorFortis HealthcareIHHihh fortisIHH HealthcareIHH in FortisIHH nomineesManaging directorTan See Leng
    Source : with agency inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok